Skip to main content

Isavuconazonium Side Effects

Medically reviewed by Last updated on Jul 9, 2023.

Applies to isavuconazonium: oral capsule. Other dosage forms:

Serious side effects of Isavuconazonium

Along with its needed effects, isavuconazonium may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking isavuconazonium:

More common

Less common or rare

Incidence not known

Other side effects of Isavuconazonium

Some side effects of isavuconazonium may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common or rare

For Healthcare Professionals

Applies to isavuconazonium: intravenous powder for injection, oral capsule.


The most common side effects were nausea, vomiting, diarrhea, headache, elevated liver chemistry tests, hypokalemia, constipation, dyspnea, cough, peripheral edema, back pain, abdominal pain, injection site reaction, and rash. Serious side effects were reported in 55% of patients. Therapy was permanently discontinued due to side effects in 14% of patients; confusional state, acute renal failure, increased blood bilirubin, convulsion, dyspnea, epilepsy, respiratory failure, and vomiting led to permanent discontinuation most often.[Ref]


Very common (10% or more): Nausea (up to 27.6%), vomiting (up to 25%), diarrhea (up to 23.7%), abdominal pain (16.7%), constipation (up to 14%)

Common (1% to 10%): Dyspepsia

Uncommon (0.1% to 1%): Abdominal distension

Frequency not reported: Gastritis, gingivitis, stomatitis[Ref]


Very common (10% or more): Hypokalemia (up to 19.1%)

Common (1% to 10%): Decreased appetite, hypomagnesemia

Uncommon (0.1% to 1%): Hypoalbuminemia, hypoglycemia, malnutrition

Frequency not reported: Hyponatremia[Ref]


Very common (10% or more): Elevated liver chemistry/laboratory tests (includes increased ALT, increased AST, increased blood alkaline phosphatase, increased blood bilirubin, increased blood lactate dehydrogenase, increased GGT, increased hepatic enzyme, abnormal hepatic function, hyperbilirubinemia, abnormal liver function test, increased transaminases; up to 17.1%)

Common (1% to 10%): Elevated liver transaminases (ALT or AST)

Uncommon (0.1% to 1%): Hepatitis, hepatomegaly

Frequency not reported: Cholecystitis, cholelithiasis, hepatic failure, cholestasis[Ref]

Elevated liver transaminases (ALT or AST) greater than 3 times the upper limit of normal (3 x ULN) and greater than 10 x ULN were reported in 4.4% and 1.2% of patients, respectively.[Ref]


Very common (10% or more): Dyspnea (up to 17.1%), cough (12%)

Common (1% to 10%): Acute respiratory failure

Uncommon (0.1% to 1%): Bronchospasm, tachypnea, hemoptysis, epistaxis[Ref]

Nervous system

Very common (10% or more): Headache (up to 17%)

Common (1% to 10%): Somnolence

Uncommon (0.1% to 1%): Convulsion, syncope, dizziness, paresthesia, encephalopathy, presyncope, peripheral neuropathy, dysgeusia, vertigo

Frequency not reported: Epilepsy, hypoesthesia, migraine, stupor, tremor, tinnitus[Ref]


Very common (10% or more): Peripheral edema (up to 15.2%), fatigue (10.5%)

Common (1% to 10%): Chest pain

Uncommon (0.1% to 1%): Malaise, asthenia

Frequency not reported: Infusion-related reactions (including hypotension, dyspnea, chills, dizziness, paresthesia, hypoesthesia), catheter thrombosis, chills, fall[Ref]


Very common (10% or more): Insomnia (10.5%)

Common (1% to 10%): Delirium (includes agitation, confusional state, delirium, disorientation, mental status changes), anxiety

Uncommon (0.1% to 1%): Depression

Frequency not reported: Confusion, hallucination[Ref]


Very common (10% or more): Renal failure (10.1%)

Frequency not reported: Acute renal failure[Ref]


Very common (10% or more): Back pain (up to 10.1%)

Frequency not reported: Myositis, bone pain, neck pain[Ref]


Common (1% to 10%): Hypotension, thrombophlebitis

Uncommon (0.1% to 1%): Atrial fibrillation, atrial flutter, bradycardia, reduced QT interval on ECG/shortened ECG QT, palpitations, supraventricular extrasystoles, supraventricular tachycardia, tachycardia, ventricular extrasystoles, circulatory collapse

Frequency not reported: Cardiac arrest[Ref]


Common (1% to 10%): Rash, pruritus

Uncommon (0.1% to 1%): Alopecia, dermatitis, petechiae, drug eruption

Frequency not reported: Exfoliative dermatitis, erythema, urticaria[Ref]


Common (1% to 10%): Injection site reaction[Ref]


Uncommon (0.1% to 1%): Neutropenia, thrombocytopenia, leukopenia, pancytopenia, anemia

Frequency not reported: Agranulocytosis[Ref]


Uncommon (0.1% to 1%): Hypersensitivity[Ref]


Frequency not reported: Hematuria, proteinuria[Ref]


Frequency not reported: Optic neuropathy[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Cresemba (isavuconazonium). Astellas Pharma US, Inc. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.